BRINTELLIX FILM-COATED TABLETS 5MG

H.Lundbeck A/S (DENMARK)🇸🇬 Health Sciences Authority

Approval Date: Nov 17, 2014
Approval ID: 2a1d31771714bd87
Company: H.Lundbeck A/S (DENMARK)
Type: Therapeutic

Approval Details

Approval Id: 2a1d31771714bd87
Drug Name: BRINTELLIX FILM-COATED TABLETS 5MG
Product Name: BRINTELLIX FILM-COATED TABLETS 5MG
Approval Number: SIN14665P
Approval Date: 2014-11-17
Registrant: ZUELLIG PHARMA PTE. LTD.
Licence Holder: ZUELLIG PHARMA PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: TABLET, FILM COATED
Dosage: 4.2 Posology and method of administration Posology The starting and recommended dose of Brintellix is 10 mg vortioxetine once daily in adults less than 65 years of age. Depending on individual patient response, the dose may be increased to a maximum of 20 mg vortioxetine once daily or decreased to a minimum of 5 mg vortioxetine once daily. After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the antidepressive response. Treatment discontinuation A gradual reduction in dosage may be considered to avoid the occurrence of discontinuation symptoms (see section 4.8 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). However, there is insufficient data to provide specific recommendations for a tapering schedule for patients treated with Brintellix. Special populations Elderly patients The lowest effective dose of 5 mg vortioxetine once daily should always be used as the starting dose in patients ≥ 65 years of age. Caution is advised when treating patients ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Cytochrome P450 inhibitors Depending on individual patient response, a lower dose of vortioxetine may be considered if a strong CYP2D6 inhibitor (e.g. bupropion, quinidine, fluoxetine, paroxetine) is added to vortioxetine treatment (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Cytochrome P450 inducers Depending on individual patient response, a dose adjustment of vortioxetine may be considered if a broad cytochrome P450 inducer (e.g., rifampicin, carbamazepine, phenytoin) is added to vortioxetine treatment (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Paediatric population Brintellix should not be used in paediatric patients (under 18 years of age) with major depressive disorder (MDD) because efficacy has not been demonstrated (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). The safety of Brintellix in paediatric patients is described in section 4.4, 4.8 and 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Renal or hepatic impairment No dose adjustment is needed based on renal or hepatic function (see section 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Method of administration Brintellix is for oral use. The film-coated tablets can be taken with or without food.
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Brintellix is indicated for the treatment of major depressive episodes in adults.
Contraindications: 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Concomitant use with nonselective monoamine oxidase inhibitors (MAOIs) or selective MAO-A inhibitors (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Atc Code: N06AX26
Atc Item Name: vortioxetine
Pharma Manufacturer Name: LUNDBECK SINGAPORE PTE. LTD.

Active Ingredients

Vortioxetine (as hydrobromide 6.355 mg)

5.00mg

VORTIOXETINE (AS HYDROBROMIDE 6.355 MG)

5 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Nov 17, 2014

Approval ID

2a1d31771714bd87

Type

Therapeutic

Back to HSA Approvals